drugset / Trial / NCT02502500

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

NCT02502500

Phase 1 Completed 12 enrolled Akebia Therapeutics
RandomizedSingle-groupOpen-labelOther

Summary

To assess the single dose pharmacokinetics (PK) of celecoxib in healthy subjects when administered alone and following multiple daily doses of AKB-6548.

Timeline

Start
2015-07
Primary completion
2015-07
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified
Subject Vadadustat Small molecule

Indications

No indication recorded.